ALS TDI - ALS Therapy Development Institute. The world's most advanced research laboratory dedicated to ALS.
article DETAILS

ALS TDI Researchers to Present at Two Upcoming Scientific Conferences

09/04/2009

Several ALS TDI researchers have been invited to present the latest work of the Institute at two important science meetings this Fall and Winter. We applaud our scientists for their work and for their participation in these events. Recaps of their presentations will be part of the final Research Update of 2009 as the meetings require that data be embargoed until after it is presented. The following is a current list of presentations (subject to change):

Neuroscience 2009, Oct. 17-21, in Chicago, Ill. ALS TDI: Neuroscience 2009

Monica Wang

“Sciatic nerves of transgenic SOD1 ALS mice secrete cytokines and chemokines that affect macrophage recruitment and activation”

Nanosymposium - 304: Motor Neuron Disease Models and Mechanisms I

Monday October 19

8:00-8:15am

John Lincecum, Ph.D.

“Macrophage selectively accumulate within distal nerves in a murine model of amyotrophic lateral sclerosis”

Nanosymposium - 304.1: Motor Neuron Disease Models and Mechanisms I

Monday October 19

9:30-9:45am

Steve Perrin, Ph.D.

“Anti-CD40L monoclonal antibody therapy improves disease progression and survival in a murine model of amyotrophic lateral sclerosis”

Nanosymposium - 699: Motor Neuron Disease and Ataxia Therapeutics

Wednesday October 21

8:30-8:45am

Fernando Vieira, M.D.

“Chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS has no therapeutic benefit”

Nanosymposium - 699: Motor Neuron Disease and Ataxia Therapeutics

Wednesday October 21

8:45-9:00am

Al Gill, Ph.D.

“Chronic apocynin dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS has no therapeutic benefit”

Nanosymposium - 699: Motor Neuron Disease and Ataxia Therapeutics

Wednesday October 21

9:15-9:30am

20th International Symposium on ALS/MND, Dec. 7-11 in Berlin, Germany

Steve Perrin, Ph.D.

“Anti-CD40L monoclonal antibody therapy improves disease progression and survival in a murine model of amyotrophic lateral sclerosis”

Session 9A: Inflammatory/Immunological and Gliala Contribution to Motor Neuron Degeneration

Thursday, Dec. 10

9:30AM

-The Institute will also present 4 posters at this event on its work. John McCarty, Ph.D. and John Lincecum, Ph.D. will attend this event to assist in these displays and to participate in other portions of this conference.

Internal Symposium on ALS/MND

Berlin 2009